Shares of GenMark Diagnostics Inc. (GNMK) slid 7 percent in after-hours trade on the Nasdaq, after the company slashed its revenue outlook for the year ending December 2013.
The company cited additional uncertainties relating to the future revenue contribution from its largest customer, along with persisting reimbursement and other challenges affecting the emerging pharmacogenomics market sector as the reason for the pruned outlook.
For the full year, the company now expects revenue of about $30 million, down from prior guidance of about $35 million.
Analysts polled by Thomson Reuters currently expect revenue of $35.11 million for the full year.
For comments and feedback: editorial@rttnews.com